Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Year: 2019
Type: review
Study designs: Systematic Review, Meta-Analysis
Source: Lung Cancer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune checkpoint inhibitors, non-small cell lung cancer, first-line therapy, pembrolizumab, atezolizumab, bevacizumab, combination chemotherapy, PD-L1 expression, progression-free survival, overall survival, lung squamous cell carcinoma, non-squamous cell lung cancer, treatment comparison, circumstantial evidence
Open Access status: closed
OpenAlex ID: W2946950110
